![]() |
Name |
(3R,4R)-4-Hydroxy-de-O-methyllasiodiplodin
|
Molecular Formula | C16H22O5 | |
IUPAC Name* |
(4R,5R)-5,14,16-trihydroxy-4-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),13,15-trien-2-one
|
|
SMILES |
C[C@@H]1[C@@H](CCCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1)O
|
|
InChI |
InChI=1S/C16H22O5/c1-10-13(18)7-5-3-2-4-6-11-8-12(17)9-14(19)15(11)16(20)21-10/h8-10,13,17-19H,2-7H2,1H3/t10-,13-/m1/s1
|
|
InChIKey |
ZTMGIUWYKJLEDJ-ZWNOBZJWSA-N
|
|
Synonyms |
(3R,4R)-4-Hydroxy-de-O-methyllasiodiplodin
|
|
CAS | NA | |
PubChem CID | 102233599 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 294.34 | ALogp: | 3.8 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 21 | QED Weighted: | 0.639 |
Caco-2 Permeability: | -4.928 | MDCK Permeability: | 0.00002830 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.017 |
Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.986 |
30% Bioavailability (F30%): | 0.987 |
Blood-Brain-Barrier Penetration (BBB): | 0.421 | Plasma Protein Binding (PPB): | 94.74% |
Volume Distribution (VD): | 1.354 | Fu: | 4.52% |
CYP1A2-inhibitor: | 0.959 | CYP1A2-substrate: | 0.591 |
CYP2C19-inhibitor: | 0.566 | CYP2C19-substrate: | 0.068 |
CYP2C9-inhibitor: | 0.336 | CYP2C9-substrate: | 0.942 |
CYP2D6-inhibitor: | 0.932 | CYP2D6-substrate: | 0.388 |
CYP3A4-inhibitor: | 0.422 | CYP3A4-substrate: | 0.082 |
Clearance (CL): | 9.975 | Half-life (T1/2): | 0.845 |
hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.085 |
Drug-inuced Liver Injury (DILI): | 0.348 | AMES Toxicity: | 0.111 |
Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.332 |
Skin Sensitization: | 0.868 | Carcinogencity: | 0.039 |
Eye Corrosion: | 0.025 | Eye Irritation: | 0.934 |
Respiratory Toxicity: | 0.198 |